Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Denali Therapeutics (DNLI) Leases (2019 - 2025)

Denali Therapeutics (DNLI) has disclosed Leases for 7 consecutive years, with $48.5 million as the latest value for Q4 2025.

  • Quarterly Leases rose 2.1% to $48.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.5 million through Dec 2025, up 2.1% year-over-year, with the annual reading at $48.5 million for FY2025, 2.1% up from the prior year.
  • Leases for Q4 2025 was $48.5 million at Denali Therapeutics, up from $20.0 million in the prior quarter.
  • The five-year high for Leases was $48.5 million in Q4 2025, with the low at $20.0 million in Q3 2025.
  • Average Leases over 5 years is $30.7 million, with a median of $30.0 million recorded in 2022.
  • Peak annual rise in Leases hit 93.21% in 2025, while the deepest fall reached 15.52% in 2025.
  • Over 5 years, Leases stood at $30.7 million in 2021, then fell by 1.0% to $30.4 million in 2022, then decreased by 14.42% to $26.0 million in 2023, then surged by 82.48% to $47.5 million in 2024, then increased by 2.1% to $48.5 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $48.5 million, $20.0 million, and $47.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.